The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: A meta-analysis

Wspolczesna Onkologia

Volumn 18, Issue 1, 2014, Pages 39-47

  Liu, Ying ^a   He, Shuhua ^a   Ding, Yi ^a   Huang, Jing ^a   Zhang, Yuqing ^a   Chen, Longhua ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma; Meta analysis; Non small cell lung; Thalidomide

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; THALIDOMIDE;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 84898471177     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.40782     Document Type: Article

References (36)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
2. Pérol M, Arpin D. Angiogenesis and lung cancer. Bull Cancer 2007; 94 Spec No: S220-S31.
3. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase iii study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage iii non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-9.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
7. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 931-4.
8. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86: 558-63.
9. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, Lee YC. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001; 19: 432-41.
10. Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ, Landreneau RJ. Vascular endothelial growth factor expression in stage i non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001; 8: 72-9.
11. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005; 23: 3243-56.
12. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.
13. Reyes-Terán G, Sierra-Madero JG, Martínez del Cerro V, Arroyo- -Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501-7.
14. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802-11.
15. DeCicco KL, Tanaka T, Andreola F, De Luca LM. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway. Carcinogenesis 2004; 25: 1805-12.
16. Jazieh AR, Komrokji R, Gupta A, Patil S, Flora D, Knapp M, Issa M, Abdel Karim N. Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer. Cancer Invest 2009; 27: 932-6.
17. Miller AA, Case D, Atkins JN, Giguere JK, Bearden JD. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006; 1: 832-6.
18. Merchant JJ, Kim K, Mehta MP, Ripple GH, Larson ML, Brophy DJ, Hammes LC, Schiller JH. Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer. Clin Lung Cancer 2000; 2: 48-54.
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
20. Geyer HL, Viggiano RW, Lacy MQ, Witzig TE, Leslie KO, Mikhael JR, Stewart K. Acute lung toxicity related to pomalidomide. Chest 2011; 140: 529-33.
21. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta- analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
24. Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol 2012; 30: 616-22.
25. Lee SM, Rudd R, Woll PJ, et al. Randomized double-blind placebo- controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 5248-54.
26. Jiang WM, Wang Y, Jiang H, et al. The control clinical study on the treatment of advanced non-small cell lung cancer by TGP regimen and GP regimen. Chinese Clin Oncol 2009; 15: 798-801.
27. He HJ, Hu W. Efficacy evaluation of Thalidomide combined with chemoradiotherapy in the treatment of 36 cases with NSCLC stage III. J Chinese Oncol 2011; 17: 202-4.
28. He QS, Yi T, Luo B, Zhang X. A randomized trial of NVB plus DDP with versus without thalidomide in the treatment of advanced non small cell lung cancer. Zhongguo Fei Ai Za Zhi 2008; 11: 264-7.
29. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008; 27: 111-35.
30. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-5.
31. Yu Y, Xu X, Du Z, Shi M. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials. Cancer Chemother Pharmacol 2012; 69: 1265-75.
32. Riedel RF, Crawford J, Dunphy F, Herndon JE 2nd, Garst J, Kelley MJ. Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer 2006; 54: 431-2.
33. Dowlati A, Subbiah S, Cooney M, et al. Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer 2007; 56: 377-81.
34. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 1031-6.
35. Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-505.
36. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.